← Eichor
Study identifier: NCT06723717 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Efficacy of Daily IV Administration of Dornase Alfa up to 14 Days Post Subarachnoid Hemorrhage on Functional Independence at 6 Months

Condition: Ruptured Aneurysm of Intracranial Artery · SAH (Subarachnoid Hemorrhage) · Delayed Cerebral Ischemia  ·  Sponsor: Fondation Ophtalmologique Adolphe de Rothschild

PhasePhase 2
Planned participants304
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Subarachnoid hemorrhage due to aneurysm rupture (SAH) results in high mortality, while survivors frequently suffer reduced quality of life and even loss of autonomy, particularly in the active population. A significant proportion of this morbidity and mortality is linked to the occurrence of delayed cerebral ischemia (DCI), defined as a new focal neurological deficit or reduced level of consciousness unrelated to the treatment of the aneurysm or a concomitant condition. DCI mainly occurs between days 4 and 14 after SAH, with an estimated incidence of 30%, and is significantly associated with an unfavorable functional prognosis at 3 months. Currently, the only treatment for post-SAH DCI is to prevent or reverse the onset of vasospasm, with limited efficacy, for example through nimodipine administration or hemodynamic optimization. However, according to existing data, vasospasm is not the only cause of DCI, as it may occur elsewhere than in the arterial territory affected by vasospasm, or even in the absence of any vasospasm at all. Recent reviews of the literature highlight the role of microvascular thrombo-inflammation in the pathophysiology of DCI. This phenomenon begins as soon as SAH occurs, with the appearance of multiple microvascular obstructions responsible for ischemia of downstream territories and loss of distal autoregulatory capacity. Among the effectors of thrombo-inflammation, the NETose phenomenon (production of NETs - Neutrophil Extracellular Traps or extrace…

This description comes directly from the study's public registry record.

Talk to the study team

Amelie Yavchitz  ·  +33148036454  ·  ayavchitz@for.paris

Francois Delvoye, MD  ·  fdelvoye@for.paris

Always discuss trial participation with your own doctor first.

Locations (6)

CHU de GrenobleGrenoble, Grenoble, FranceRecruiting
HCL de LyonLyon, Lyon, FranceRecruiting
CHU de MontpellierMontpellier, Montpellier, FranceRecruiting
CHU PoitiersPoitiers, Poitiers, FranceRecruiting
CHU StrasbourgStrasbourg, Strasbourg, FranceRecruiting
Hôpital FOCHSuresnes, Île-de-France Region, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06723717